Andrew Berens
Stock Analyst at Leerink Partners
(2.31)
# 2,671
Out of 5,240 analysts
99
Total ratings
45.78%
Success rate
-1.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Outperform | $28 → $55 | $20.11 | +173.50% | 2 | May 14, 2026 | |
| COGT Cogent Biosciences | Maintains: Outperform | $14 → $15 | $32.97 | -54.50% | 6 | Jun 13, 2022 | |
| ZYME Zymeworks | Maintains: Outperform | $52 → $58 | $23.80 | +143.70% | 11 | Mar 3, 2026 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $8 | $6.89 | +16.19% | 1 | Jan 23, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $28.15 | +42.12% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $101.48 | +46.83% | 3 | Nov 17, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $5.12 | +192.97% | 1 | Oct 31, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $8.23 | +203.77% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $135.10 | -55.59% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $8.95 | +0.56% | 6 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $6 | $1.89 | +217.46% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $880 → $762 | $699.02 | +9.01% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.19 | +934.48% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $129.53 | -25.89% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $94.80 | -17.72% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $15.80 | +77.27% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $182.17 | -56.63% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $4.00 | +575.00% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $15.71 | +59.13% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $7.73 | +417.46% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $3.50 | +1,814.29% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $18.22 | +9.77% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $9.21 | -13.14% | 7 | Jul 14, 2017 |
Tango Therapeutics
May 14, 2026
Maintains: Outperform
Price Target: $28 → $55
Current: $20.11
Upside: +173.50%
Cogent Biosciences
Jun 13, 2022
Maintains: Outperform
Price Target: $14 → $15
Current: $32.97
Upside: -54.50%
Zymeworks
Mar 3, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $23.80
Upside: +143.70%
Relmada Therapeutics
Jan 23, 2026
Upgrades: Outperform
Price Target: $8
Current: $6.89
Upside: +16.19%
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $28.15
Upside: +42.12%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $101.48
Upside: +46.83%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $5.12
Upside: +192.97%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $8.23
Upside: +203.77%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $135.10
Upside: -55.59%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $8.95
Upside: +0.56%
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $1.89
Upside: +217.46%
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $699.02
Upside: +9.01%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $3.19
Upside: +934.48%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $129.53
Upside: -25.89%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $94.80
Upside: -17.72%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $15.80
Upside: +77.27%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $182.17
Upside: -56.63%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $4.00
Upside: +575.00%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $15.71
Upside: +59.13%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $7.73
Upside: +417.46%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $3.50
Upside: +1,814.29%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $18.22
Upside: +9.77%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $9.21
Upside: -13.14%